CompletedPhase 1NCT02116712

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tony Eissa
Principal Investigator
Tony Eissa, MD
Baylor College of Medicine
Intervention
Saracatinib(drug)
Enrollment
9 enrolled
Eligibility
18-65 years · All sexes
Timeline
20142015

Study locations (3)

Collaborators

University of Texas · University of Cincinnati

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02116712 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials